Key Takeaways
- The resignation of CBER director Peter Marks hit biopharma stocks hard as the FDA leadership shakeup increased regulatory uncertainty, particularly for vaccines and cell and gene therapies.
News that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation,...